Clindamycin

Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older

Retrieved on: 
Wednesday, January 10, 2024
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, CDAD, Development, Woman, Hydrogen chloride, Hypersensitivity, Patient, OGN, Frustration, Thermoregulation, Gynaecology, History, Bacterial vaginosis, Clostridioides, Environment, Recurrence, Research and development, BV, Bacteria, Clindamycin, Lincomycin, Infection, American College

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).
  • Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.
  • If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued.
  • Information about XACIATO, and the eVoucher instant savings coupon for eligible patients, can be found at XACIATO.com .

Saudi Arabia Antibiotics Markets, Competition, Forecast & Opportunities, 2027 - Cephalosporin, Penicillin, Amoxicillin, Azithromycin, Clindamycin, Tetracycline - ResearchAndMarkets.com

Retrieved on: 
Friday, January 27, 2023
Infectious Diseases, Pharmaceutical, Health, Capsule, Administration, Penicillin, Urinary tract infection, Infection, Government, Virus, Viral, Investment, Cephalosporin, COVID-19, Disorder, Saudi Food and Drug Authority, Drug development, Market, Route of administration, Certification, Research, Ministry, Death, SFDA, Antibody, Disease, Sanofi, Growth, Spectrum, Bacteria, Clindamycin, Tablet, Grindeks, Pharmaceutical industry, Vaccine, Arms industry, Azithromycin, Amoxicillin, Sepsis, Tetracycline

Saudi Arabia antibiotics market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of increasing instances of infectious diseases.

Key Points: 
  • Saudi Arabia antibiotics market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of increasing instances of infectious diseases.
  • Saudi Arabia pharmaceutical industry grossed USD8.35 billion in the year 2019 that further registered growth of USD10.19 billion in 2020.
  • promotes the requirement for the antibiotics and thus supports the growth of the Saudi Arabia antibiotics market in the next five years.
  • Company Profiles: Detailed analysis of the major companies present in Saudi Arabia antibiotics market.

Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region

Retrieved on: 
Wednesday, November 23, 2022
Risk, Approximation error, Temperature, Infection, Acquisition, Sinusitis, Clindamycin, ACS, Marketing, Pharmaceutical industry

Under the agreement, Navamedic acquires the rights and Marketing Authorizations for the unique Clindamycin ready-to-administer bags developed and manufactured by InfoRLife AS.

Key Points: 
  • Under the agreement, Navamedic acquires the rights and Marketing Authorizations for the unique Clindamycin ready-to-administer bags developed and manufactured by InfoRLife AS.
  • Navamedic already markets Clindamycin in traditional ampoules as part of the large portfolio of antibiotics acquired from ACS Dobfar in 2020.
  • The innovative ready-to-use product will thus complement this portfolio.
  • The transfer of the marketing authorizations will be initiated within short and the product is expected to be on the market under the Navamedic label from early 2023.

ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection

Retrieved on: 
Monday, September 12, 2022
Pseudomonas aeruginosa, Trial of the century, Infection, COVID-19, FDA, Hospital, Levofloxacin, Recurrence, Forward-looking statement, Maintenance, Lysin, U.S. Securities and Exchange Commission, Patient, Clinical trial, Breakthrough therapy, SOC, Pneumonia, Salvage therapy, Cons, Nasdaq, DLA, MRSA, Clindamycin, Bacteria, Death, Osteomyelitis, Endocarditis, Security (finance), GLOBE, State, Campaign, Șaeș, Biofilm, Peptide, Subclinical infection, Enterobacter, Acinetobacter baumannii, Pharmaceutical industry, Staphylococcus

The positive clinical data demonstrated in these patients underpins the potential to prosecute exebacase in a blinded clinical study of patients with chronic or recurrent prosthetic joint infections caused by MRSA or coagulase-negative Staph, stated Roger J. Pomerantz, M.D., ContraFects President, Chief Executive Officer, and Chairman.

Key Points: 
  • The positive clinical data demonstrated in these patients underpins the potential to prosecute exebacase in a blinded clinical study of patients with chronic or recurrent prosthetic joint infections caused by MRSA or coagulase-negative Staph, stated Roger J. Pomerantz, M.D., ContraFects President, Chief Executive Officer, and Chairman.
  • The first cohort included patients suffering their first episode of CoNS knee PJI.
  • The second cohort included patients suffering from a complex episode of multi-drug resistant CoNS knee PJI.
  • The LysinDAIR procedure was followed by three months of antibiotics plus additional suppressive antimicrobial therapy.

Amneal launches 4 new Generic products, including Vasopressin single-dose

Retrieved on: 
Thursday, August 11, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, FDA, Vasopressin, Intellectual property, USP, U.S. Securities and Exchange Commission, Risk, Industry, Forward-looking statement, NYSE, Growth, Investment, Amneal Pharmaceuticals, Security (finance), Research, Annual report, COVID-19, Company, Central nervous system, Degenerative disease, Famotidine, Generic, Federation, Ownership, Private Securities Litigation Reform Act, CGT, Weather, Common stock, Birth control, Medical device, Risk management, Clindamycin

Each year, we target 20 to 30 new product launches in generics, and we are on-track to achieving that goal again in 2022.

Key Points: 
  • Each year, we target 20 to 30 new product launches in generics, and we are on-track to achieving that goal again in 2022.
  • Vasopressin injection 1mL is a generic version of the antidiuretic hormone Vasostrict.
  • Famotidine for oral suspension (40 mg/5 mL), an H2 antagonist, is a generic equivalent for Pepcid.
  • This product received Competitive Generic Therapy (CGT) approval designation as Amneal continues to have the highest number of CGT designated products in the industry.

Hims & Hers Expands Customizable, Compounded Skincare Offerings With Hims Overnight Anti-Aging Duo, Hers Clear Skin System

Retrieved on: 
Wednesday, September 22, 2021
Women, Men, Specialty, Other Health, Health, Cosmetics, Consumer, Pharmaceutical, Retail, Cream, Duo, Anti-aging cream, Health minister, Hims & Hers Health, Hers, Health, Atomic, Mental health, Clindamycin, Dermatology, Innovation, Nicotinamide, Hyaluronic acid, Tretinoin, NYSE, SVP, Skin, Cosmetics

Hims Overnight Anti-Aging Duo was developed with dermatologists to combat wrinkles and sun damage while moisturizing and nourishing skin. It includes a customizable prescription Anti-Aging Cream mixed with three clinical ingredients and available in three different strengths, as well as the nonprescription Goodnight Wrinkle Cream made with hyaluronic acid. Both the customizable prescription Anti-Aging Cream and Goodnight Wrinkle Cream will also continue to be available for purchase individually on ForHims.com. Those consumers looking to purchase the prescription cream -- as part of the Duo or individually -- will need to first complete a consultation with a healthcare provider through the Hims & Hers platform to see if a prescription treatment is medically recommended and will be able to purchase the prescription cream only if deemed appropriate by the healthcare provider. The Goodnight Wrinkle Cream is available for purchase directly from Hims without a prescription.

Key Points: 
  • Hims & Hers Health, Inc. (Hims & Hers) (NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, recently launched Hims Overnight Anti-Aging Duo and a customized Hers Clear Skin System .
  • Skincare is a lifelong journey and certainly not a one-size-fits-all proposition, said Hilary Coles, co-founder and SVP of Brand & Innovation, Hims & Hers.
  • Hims Overnight Anti-Aging Duo was developed with dermatologists to combat wrinkles and sun damage while moisturizing and nourishing skin.
  • Hers Clear Skin System provides consumers with the ability to have both clean and hydrated skin with the support of an experienced medical professional.

Solaris Pharma Receives Approval for First Generic Version of Clindagel® (clindamycin phosphate EQ 1%)

Retrieved on: 
Monday, August 23, 2021
Solaris, GLOBE, Company, Bausch Health, Clindamycin, Day 1 (building), Food, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Solaris Pharma Corporation (Solaris or the Company) announced today that the Company has received an abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA or Agency) for the first generic version of Clindagel (clindamycin phosphate EQ 1%).

Key Points: 
  • BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Solaris Pharma Corporation (Solaris or the Company) announced today that the Company has received an abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA or Agency) for the first generic version of Clindagel (clindamycin phosphate EQ 1%).
  • Clindamycin phosphate EQ 1% topical gel is the generic version of Clindagel, a registered trademark of Bausch Health.
  • Solaris is pleased to provide patients access to this first-to-market generic of Clindagel.
  • We are excited to support Solaris on this approval and be their reliable manufacturing partner on this product.

Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021

Retrieved on: 
Monday, July 26, 2021
International Space Station, Clindamycin, Organochlorides, Thioethers, Compagnies Républicaines de Sécurité, Clinical medicine, Commercial Resupply Services, Bacterial vaginosis, Medicine, Chemistry

SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, PhD, the company’s Chief Scientific Officer, will present data from preclinical and clinical studies related to DARE-BV1 at the 2021 Controlled Release Society (CRS) Virtual Annual Meeting on July 27th. Daré submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for DARE-BV1 for the treatment of bacterial vaginosis in June of 2021.

Key Points: 
  • DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
  • Find out more information about the 2021 CRS Virtual Annual Meeting by visiting the CRS website: https://www.controlledreleasesociety.org/events/2021-crs-virtual-annual-... .
  • Dr. Friends presentation will be available following the conclusion of the 2021 CRS Virtual Annual Meeting under Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com .
  • Dar cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

Retrieved on: 
Monday, April 26, 2021
Anti-acne preparations, Sexually transmitted diseases and infections, Probiotics, Clindamycin, Organochlorides, Thioethers, Bacterial vaginosis, Organ systems, Chemistry, Drugs

DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.

Key Points: 
  • DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
  • Patients were evaluated during three clinic visits: Day 1 (screening and randomization visit), Day 7-14 (assessment visit), and Day 21-30 (test-of-cure visit).
  • \xe2\x80\x9cIn the DARE-BVFREE trial, DARE-BV1 was well-tolerated and demonstrated clinical cure efficacy rates superior to those shown by current branded prescription products for treatment of bacterial vaginosis.
  • You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.

Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update

Retrieved on: 
Tuesday, March 30, 2021
Anti-acne preparations, Sexually transmitted diseases and infections, Clindamycin, Organochlorides, Thioethers, Bacterial vaginosis, Darzhavna Aeroplanna Rabotilnitsa, Chemistry, Drugs, Organic compounds

Despite the unique challenges posed during 2020, we achieved two important corporate firsts in 2020.

Key Points: 
  • Despite the unique challenges posed during 2020, we achieved two important corporate firsts in 2020.
  • Dar solution: Novel, investigational thermosetting bioadhesive hydrogel formulated with clindamycin phosphate 2% as a first-line, single-administration treatment for bacterial vaginosis.
  • Dar will host a conference call and live webcast today at4:30 p.m. Eastern Timeto review the company's financial results for the year ended December 31, 2020 and to provide a company update.
  • Dar Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for womens health.